Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free ASND Stock Alerts $136.93 -6.25 (-4.37%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$136.19▼$140.5950-Day Range$140.17▼$159.4052-Week Range$66.03▼$161.00Volume376,771 shsAverage Volume368,318 shsMarket Capitalization$7.97 billionP/E RatioN/ADividend YieldN/APrice Target$173.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Ascendis Pharma A/S alerts: Email Address Ascendis Pharma A/S MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside26.5% Upside$173.25 Price TargetShort InterestBearish6.18% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.15) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.14 out of 5 starsMedical Sector535th out of 908 stocksPharmaceutical Preparations Industry238th out of 421 stocks 4.4 Analyst's Opinion Consensus RatingAscendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.18% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Ascendis Pharma A/S has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASND. Previous Next 1.8 News and Social Media Coverage News SentimentAscendis Pharma A/S has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Ascendis Pharma A/S this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.15) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -14.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -14.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Ascendis Pharma A/S Stock (NASDAQ:ASND)Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Read More ASND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASND Stock News HeadlinesApril 25, 2024 | globenewswire.comAscendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024April 24, 2024 | markets.businessinsider.comUnited Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 24, 2024 | markets.businessinsider.comAscendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic HypoparathyroidismApril 24, 2024 | globenewswire.comUnited Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismApril 23, 2024 | americanbankingnews.comAscendis Pharma A/S's (ASND) Equal Weight Rating Reaffirmed at Morgan StanleyApril 20, 2024 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Stock Rating Reaffirmed by Cantor FitzgeraldApril 12, 2024 | benzinga.comAscendis Pharma's Options Frenzy: What You Need to KnowApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 7, 2024 | seekingalpha.comWeek In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 BillionApril 4, 2024 | benzinga.comHere's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 YearsApril 2, 2024 | msn.comRoivant announces $1.5B share buyback, positive Phase 2 dataApril 2, 2024 | finance.yahoo.comBiotech With 520% Sales Growth Nears Next Buy PointMarch 22, 2024 | finance.yahoo.comAre Medical Stocks Lagging AdaptHealth (AHCO) This Year?March 22, 2024 | finance.yahoo.comTwo Health Care Stocks Outperform S&P 500, Offer EntriesMarch 22, 2024 | finance.yahoo.comAscendis Pharma A/S (ASND) Rose on Positive Trial ResultsMarch 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)March 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ascendis Pharma Amid Favorable Market Dynamics and Strong TransCon PTH OutlookMarch 14, 2024 | msn.comAurobindo Pharma restarts aseptic product distribution; shares trade higherMarch 7, 2024 | finance.yahoo.comAscendis Pharma A/S (ASND) Faced R&D Setbacks in Q4March 4, 2024 | globenewswire.comAscendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024February 27, 2024 | morningstar.comAscendis Pharma A/S ADRFebruary 25, 2024 | benzinga.com$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 TodayFebruary 22, 2024 | money.usnews.comAscendis Pharma A/S - ADRFebruary 15, 2024 | finance.yahoo.comAscendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?February 15, 2024 | msn.comAre Medical Stocks Lagging Ascendis Pharma (ASND) This Year?February 15, 2024 | finance.yahoo.comAre Medical Stocks Lagging Ascendis Pharma (ASND) This Year?See More Headlines Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ASND CUSIPN/A CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees879Year FoundedN/APrice Target and Rating Average Stock Price Target$173.25 High Stock Price Target$260.00 Low Stock Price Target$113.00 Potential Upside/Downside+26.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($9.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-521,070,000.00 Net Margins-180.61% Pretax Margin-177.77% Return on Equity-16,574.15% Return on Assets-55.10% Debt Debt-to-Equity RatioN/A Current Ratio3.56 Quick Ratio2.50 Sales & Book Value Annual Sales$288.08 million Price / Sales27.67 Cash FlowN/A Price / Cash FlowN/A Book Value($2.73) per share Price / Book-50.16Miscellaneous Outstanding Shares58,220,000Free Float34,934,000Market Cap$7.97 billion OptionableOptionable Beta0.50 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jan Moller Mikkelsen (Age 64)President, CEO, Member of Executive Board & Executive Director Mr. Scott T. Smith (Age 50)CFO, Executive VP & Member of Executive Board Ms. Lotte Sonderbjerg (Age 63)Executive VP, Chief Administrative Officer & Member of the Executive Board Mr. Michael Wolff Jensen L.L.M. (Age 53)Executive VP, Chief Legal Officer & Member of the Executive Board Mr. Mads BodenhoffSenior VP of Finance & Principal Accounting OfficerMr. Timothy J. LeeSenior Director of Investor RelationsMr. Flemming Steen Jensen (Age 63)Executive Vice President of Product Supply & Quality Dr. Kennett Sprogoe Ph.D. (Age 45)Executive VP and Head of Research & Product Development Dr. Stina Singel M.D. (Age 50)Ph.D., Executive VP & Head of Clinical Development for Oncology Mr. Joseph Kelly (Age 55)Head of U.S. Commercial of Endocrinology More ExecutivesKey CompetitorsLegend BiotechNASDAQ:LEGNRoivant SciencesNASDAQ:ROIVCerevel TherapeuticsNASDAQ:CEREIntra-Cellular TherapiesNASDAQ:ITCIViking TherapeuticsNASDAQ:VKTXView All CompetitorsInstitutional OwnershipSimplex Trading LLCSold 1,100 shares on 4/25/2024Ownership: 0.000%Rice Hall James & Associates LLCSold 6,471 shares on 4/23/2024Ownership: 0.279%Allspring Global Investments Holdings LLCSold 13,964 shares on 4/18/2024Ownership: 0.325%Hennion & Walsh Asset Management Inc.Bought 882 shares on 4/17/2024Ownership: 0.012%Private Ocean LLCBought 241 shares on 4/17/2024Ownership: 0.000%View All Institutional Transactions ASND Stock Analysis - Frequently Asked Questions Should I buy or sell Ascendis Pharma A/S stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ASND shares. View ASND analyst ratings or view top-rated stocks. What is Ascendis Pharma A/S's stock price target for 2024? 8 analysts have issued 12-month price targets for Ascendis Pharma A/S's shares. Their ASND share price targets range from $113.00 to $260.00. On average, they anticipate the company's share price to reach $173.25 in the next twelve months. This suggests a possible upside of 26.5% from the stock's current price. View analysts price targets for ASND or view top-rated stocks among Wall Street analysts. How have ASND shares performed in 2024? Ascendis Pharma A/S's stock was trading at $125.95 at the beginning of the year. Since then, ASND shares have increased by 8.7% and is now trading at $136.93. View the best growth stocks for 2024 here. Are investors shorting Ascendis Pharma A/S? Ascendis Pharma A/S saw a increase in short interest in April. As of April 15th, there was short interest totaling 3,600,000 shares, an increase of 7.5% from the March 31st total of 3,350,000 shares. Based on an average daily trading volume, of 348,900 shares, the short-interest ratio is currently 10.3 days. View Ascendis Pharma A/S's Short Interest. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) issued its earnings results on Wednesday, February, 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $0.49. The biotechnology company had revenue of $148.62 million for the quarter, compared to analysts' expectations of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative trailing twelve-month return on equity of 16,574.15%. What ETFs hold Ascendis Pharma A/S's stock? ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Innovator IBD 50 ETF (FFTY), Tema Cardiovascular and Metabolics ETF (HRTS), Virtus LifeSci Biotech Products ETF (BBP), BNY Mellon Innovators ETF (BKIV), Harbor Disruptive Innovation ETF (INNO) and American Century Focused Dynamic Growth ETF (FDG). What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA). When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.32%), Rice Hall James & Associates LLC (0.28%), Hennion & Walsh Asset Management Inc. (0.01%), Simplex Trading LLC (0.00%), GAMMA Investing LLC (0.00%) and Private Ocean LLC (0.00%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASND) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
